Journal News

JBC: Targeting semen amyloid fibrils to reduce HIV infectivity

Courtney Chandler
Oct. 1, 2016

The human immunodeficiency virus, which attacks the immune system, affects more than 1.2 million people in the U.S. There aren’t any vaccines or cures. Instead, microbicides are used to help protect against the transmission of HIV from person to person. However, the process of transmission isn’t understood fully and can involve both viral and human factors that promote infection.

Gallic acid, or GA, coats the surfaces of amyloid fibrils in semen to prevent HIV infectivity enhancement and coats the peptide precursors to prevent fibril formation.IMAGE COURTESY OF JOSIE LORICCO

In a recent paper published in the Journal of Biological Chemistry, Nadia Roan of the University of California, San Francisco, and George Makhatadze of Rensselaer Polytechnic Institute described a small molecule that prevents a specific human factor from increasing the ability of HIV to cause infection.

Researchers know that the virus itself has many factors that help it infect new hosts. There are also human factors that play a role in the transmission of HIV and a person’s susceptibility to infection. One of these factors is the ordered accumulations of misfolded proteins called amyloid fibrils. These fibrils occur naturally in human semen and have been shown to increase HIV infectivity and decrease the effectiveness of anti-HIV microbicide treatments.

The infection-promoting fibrils have been observed in the semen of both healthy and HIV-infected men. Therefore, researchers want to identify compounds that disrupt the formation of these fibrils or rid them of their infectivity-enhancing properties and reduce the sexual transmission of the virus through semen.

The investigators, led by graduate student Josie LoRicco of Rensselaer Polytechnic Institute, used a screen of small molecules to identify compounds that altered the properties of specific amyloid fibrils in semen. One molecule that came out of the screen, gallic acid, further proved to be capable of reducing HIV infectivity in the presence of semen. “Gallic acid is a small molecule found naturally in many foods, including grapes and tea,” says Makhatadze.

LoRicco, Roan, Makhatadze and colleagues further investigated gallic acid’s properties. They used atomic force and confocal microscopies in addition to several quantitative assays to characterize the interaction between gallic acid and the fibrils. Surprisingly, gallic acid did not induce disassembly of the fibrils but instead bound to their surfaces.

The investigators conducted biophysical analysis of fibrils’ surface properties to understand the nature of the interaction. They demonstrated that gallic acid limits the ability of semen fibrils to enhance HIV infection by binding to the fibrils’ surfaces and neutralizing their surface charge. Additionally, the gallic acid-coated fibrils prevent the formation of new amyloid fibrils by binding the precursor components and changing their charge characteristics.

“Gallic acid appears to do two things,” explains Makhatadze. “First, it inhibits new fibril formation. Second, it interacts with pre-existing fibrils and renders them incapable of facilitating HIV infectivity.”

The investigators suggest that gallic acid may be a useful addition to multicomponent microbicides that target both viral and human factors involved in the promotion of HIV transmission and infection. Makhatadze suggests that “such combination microbicides will be more effective at preventing transmission compared to single-component microbicides.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Courtney Chandler

Courtney Chandler is a biochemist and microbiologist in Baltimore, Md., and a careers columnist for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Meet Robert Helsley
Interview

Meet Robert Helsley

March 6, 2025

The Journal of Lipid Research junior associate editor studies chronic liver disease and was the first in his family to attend college.

From the Journals: MCP
Journal News

From the Journals: MCP

March 4, 2025

Protein acetylation helps plants adapt to light. Mapping protein locations in 3D tissues. Demystifying the glycan–protein interactome. Read about these recent papers.

Exploring life’s blueprint: Gene expression in development and evolution
In-person Conference

Exploring life’s blueprint: Gene expression in development and evolution

March 3, 2025

Meet Julia Zeitlinger and David Arnosti — two co-chairs of the ASBMB’s 2025 meeting on gene expression, to be held June 26-29, in Kansas City, Missouri.

From the journals: JLR
Journal News

From the journals: JLR

Feb. 27, 2025

Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.

New mass spectrometry assay speeds up UTI diagnosis
Journal News

New mass spectrometry assay speeds up UTI diagnosis

Feb. 25, 2025

Scientists in Quebec use liquid chromatography–mass spectrometry to reduce the time needed to test for bacteria in urine from days to minutes — and with smaller samples.

From the journals: MCP
Journal News

From the journals: MCP

Feb. 21, 2025

Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.